

Lactose Intolerance - Pipeline Insight, 2019

<https://marketpublishers.com/r/L4A2A0A2968EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: L4A2A0A2968EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Lactose Intolerance - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lactose Intolerance pipeline landscape is provided which includes the disease overview and Lactose Intolerance treatment guidelines. The assessment part of the report embraces, in depth Lactose Intolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lactose Intolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Lactose Intolerance Understanding

Lactose Intolerance (LI) is defined as a clinical syndrome characterized by pain and abdominal distention, flatulence, and diarrhea that occurs after lactose consumption. These symptoms—produced by malabsorption of lactose, a sugar found in milk and other dairy products—often result in avoidance of dairy products by afflicted individuals. Lactose malabsorption occurs because of a decreased ability to digest lactose, due to a deficiency in the levels of the enzyme lactase. Lactase breaks lactose down into two simpler sugars, glucose and galactose, which are readily absorbed into the bloodstream. This enzyme is produced by expression of the lactase-phlorizin hydrolase gene in the cells lining the small intestine. Lactose intolerance is mainly caused by genome-diet interaction and depends not only on the expression of lactase enzyme but also on the dose of lactose intake, intestinal flora, gastrointestinal motility, small intestinal bacterial overgrowth. Along with this, the sensitivity of the gastrointestinal tract to generate gas and other fermentation products due to lactose digestion. There are

several factors that influence the lactose intolerance that may include Hypolactasia, Lactase non-persistence, Lactase persistence, Lactose maldigestion, lactose malabsorption, and Lactose malassimilation.

Lactose Intolerance Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lactose Intolerance targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lactose Intolerance pipeline report covers 3+ companies. Some of the key players include Ritter Pharmaceuticals (RP-G28) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Lactose Intolerance Analytical Perspective by DelveInsight

In-depth Lactose Intolerance Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Lactose Intolerance Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Lactose Intolerance report provides an overview of therapeutic pipeline activity for Lactose Intolerance across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Lactose Intolerance therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Lactose Intolerance Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lactose Intolerance

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Lactose Intolerance to formulate effective R&D strategies

Assess challenges and opportunities that influence Lactose Intolerance R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Lactose Intolerance in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lactose Intolerance to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. LACTOSE INTOLERANCE

2.1. Lactose Intolerance Disease Overview

2.2. Lactose Intolerance History

2.3. Lactose Intolerance Symptoms

2.4. Lactose Intolerance Causes

2.5. Lactose Intolerance Pathophysiology

2.6. Lactose Intolerance Diagnosis

2.6.1. Diagnostic Guidelines

3. LACTOSE INTOLERANCE CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. LACTOSE INTOLERANCE - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment

4.1.1. Lactose Intolerance companies collaborations, Licensing, Acquisition –Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Lactose Intolerance Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Lactose Intolerance Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono / Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. LACTOSE INTOLERANCE PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. LACTOSE INTOLERANCE -PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. RP-G28- Ritter Pharmaceuticals
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. LACTOSE INTOLERANCE KEY COMPANIES

- 8.1. Celprogen
- 8.2. Ritter Pharmaceuticals
- 8.3. Eurofarma Laboratorios S.A.

9. LACTOSE INTOLERANCE KEY PRODUCTS

- 9.1. CEP 801

9.2. RP G28

9.3. Lactase Oral Tablets

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. LACTOSE INTOLERANCE - UNMET NEEDS

12. LACTOSE INTOLERANCE - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Lactose Intolerance Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Lactose Intolerance Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Lactose Intolerance companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Lactose Intolerance Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Celprogen
Ritter Pharmaceuticals
Pro Farma
Ritter Pharmaceuticals, Inc.

VenterPharma
Eurofarma Laboratorios S.A.

I would like to order

Product name: Lactose Intolerance - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/L4A2A0A2968EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L4A2A0A2968EN.html>